SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. (AARD)

A shareholder filed a securities class action against Aardvark Therapeutics (NASDAQ: AARD) on behalf of investors who bought shares in or traceable to its February 13, 2025 IPO, or purchased Aardvark securities between February 13, 2025 and May 14, 2026. The announcement signals litigation risk for the biotech company, although the release provides no details on the alleged misconduct, damages sought, or expected financial exposure.

Analysis

This is primarily a financing and governance overhang rather than a fundamental operating-data point. For a subscale biotech, litigation can widen the discount applied to future equity raises: prospective investors may demand a larger discount, increasing dilution and reducing the value of any pre-commercial pipeline optionality. The near-term stock effect is likely driven by shareholder-base turnover and headline-sensitive liquidity, not expected legal damages.

The key question over the next 1-3 months is whether the complaint identifies a disclosure issue that forces a corrective filing, revised trial interpretation, program delay, or cash-runway reassessment. A conventional plaintiff-firm announcement without a related regulatory, clinical, or guidance revision is not independently probative and often has limited persistence. Monitor AARD's cash balance, quarterly operating burn, disclosed runway, and any at-the-market or follow-on registration activity; those variables determine whether the litigation becomes economically material.

Consensus may overreact to the lawsuit headline if AARD has adequate runway through its next value-inflecting clinical readout and no new adverse underlying facts emerge. Conversely, the downside is asymmetric if the case coincides with a financing need: litigation-related uncertainty can close the IPO-window investor base and push capital raising into a weak negotiating position. There is no clear read-through to diversified biotech peers absent evidence that the alleged disclosure practice is common across the sector.

Key Decisions for Investors

• Do not initiate a directional AARD short solely on this announcement; treat it as a liquidity-risk alert. Reassess after the next 10-Q for cash runway, quarterly burn, and any expanded risk-factor or legal-proceeding disclosure.
• For existing AARD longs, reduce exposure or hedge into any near-term headline-driven strength if cash runway is below 12 months without a defined clinical catalyst; financing risk can dominate legal merits over the next 6-12 months.
• Establish a trigger for a bearish position only if AARD discloses a program delay, changes prior clinical/safety characterization, lowers guidance, or files an equity issuance vehicle. Those developments would validate a higher dilution and multiple-compression case.
• If no new company disclosure emerges and shares decline materially on litigation headlines alone, evaluate a small tactical long only after confirming sufficient runway to the next clinical catalyst; invalidate the trade on a dilutive raise or adverse regulatory/clinical update.